阿片类物质使用障碍治疗的最新进展——聚焦于长效丁丙诺啡制剂
Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.
作者信息
Soyka Michael, Franke Andreas G
机构信息
Psychiatric Hospital, University of Munich, München 80336, Germany.
University of Applied Labour Studies, Mannheim 68163, Germany.
出版信息
World J Psychiatry. 2021 Sep 19;11(9):543-552. doi: 10.5498/wjp.v11.i9.543.
Abstract
Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed.
摘要
口服美沙酮或舌下含服丁丙诺啡是阿片类物质使用障碍（OUDs）药物治疗的一线药物。目前有三种长效丁丙诺啡长效注射剂或植入剂可用于治疗OUDs：（1）CAM 2038（Buvidal），用于皮下每周和每月给药；（2）RBP - 6000（Sublocade™），作为每月一次的长效注射剂；（3）一种为期六个月的丁丙诺啡植入剂[Probuphine™]。本文讨论了这些药物的药理学、临床疗效及前景。
相似文献
1
Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.
World J Psychiatry. 2021 Sep 19;11(9):543-552. doi: 10.5498/wjp.v11.i9.543.
2
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
Pharmacopsychiatry. 2021 Jan;54(1):18-22. doi: 10.1055/a-1298-4508. Epub 2020 Nov 19.
3
[New slow-release buprenorphine formulations for optimization of opioid substitution].
Nervenarzt. 2019 Sep;90(9):932-937. doi: 10.1007/s00115-019-0783-6.
4
Prolonged-release buprenorphine formulations: Perspectives for clinical practice.
Therapie. 2020 Sep-Oct;75(5):397-406. doi: 10.1016/j.therap.2020.05.007. Epub 2020 May 18.
5
Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Am J Drug Alcohol Abuse. 2021 Sep 3;47(5):599-604. doi: 10.1080/00952990.2021.1963757. Epub 2021 Aug 18.
6
[Prolonged-release buprenorphine formulations: Perspectives for clinical practice].
Therapie. 2020 May 19. doi: 10.1016/j.therap.2020.05.008.
7
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Expert Opin Drug Deliv. 2019 Sep;16(9):907-914. doi: 10.1080/17425247.2019.1649252. Epub 2019 Aug 23.
8
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.
Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015.
9
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052.
10
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
JAMA Netw Open. 2021 May 3;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041.
引用本文的文献
1
Fatalities in opioid agonist treatment with long-acting injectable buprenorphine.
Int J Legal Med. 2025 Jun 18. doi: 10.1007/s00414-025-03535-w.
2
Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder.
BMJ Open. 2025 Feb 18;15(2):e090736. doi: 10.1136/bmjopen-2024-090736.
3
Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy.
Front Psychiatry. 2025 Jan 23;16:1500799. doi: 10.3389/fpsyt.2025.1500799. eCollection 2025.
4
Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study.
Harm Reduct J. 2024 Dec 20;21(1):221. doi: 10.1186/s12954-024-01136-1.
5
Effectiveness of opioid maintenance programs for treating drug dependence in prisons.
Rev Esp Sanid Penit. 2023 Sep-Dec;25(3):112-121. doi: 10.18176/resp.00077.
本文引用的文献
1
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
JAMA Netw Open. 2021 May 3;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041.
2
Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE).
Front Psychiatry. 2020 Dec 8;11:580863. doi: 10.3389/fpsyt.2020.580863. eCollection 2020.
3
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
J Subst Abuse Treat. 2021 May;124:108221. doi: 10.1016/j.jsat.2020.108221. Epub 2020 Dec 3.
4
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
Pharmacopsychiatry. 2021 Jan;54(1):18-22. doi: 10.1055/a-1298-4508. Epub 2020 Nov 19.
5
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
Clin Pharmacokinet. 2021 Apr;60(4):527-540. doi: 10.1007/s40262-020-00957-0. Epub 2020 Nov 2.
6
Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
Addiction. 2021 Feb;116(2):426-427. doi: 10.1111/add.15244. Epub 2020 Sep 21.
7
Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
BMJ Open. 2020 Jul 31;10(7):e034389. doi: 10.1136/bmjopen-2019-034389.
8
Retention of patients in opioid substitution treatment: A systematic review.
PLoS One. 2020 May 14;15(5):e0232086. doi: 10.1371/journal.pone.0232086. eCollection 2020.
9
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
J Clin Psychopharmacol. 2020 May/Jun;40(3):231-239. doi: 10.1097/JCP.0000000000001195.
10
Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder.
J Addict Med. 2020 Mar/Apr;14(2):99-112. doi: 10.1097/ADM.0000000000000635.
Zotero 插件